Latest progress
Recently, SAL0133 tablets, an innovative small moleculeindependently developed by Salubris, has been approved by NMPA to carry outphase I clinical trial for the treatment of mild/common COVID-19 in adults.
Preclinical studies have shown that SAL0133 cansignificantly reduce the viral load in lung tissue and improve lunginflammation in animal model of SARS-CoV-2 infection, and the dose that significantly reduced the viral load was lowerthan that of Nematavir.
Non-clinical pharmacokinetic study confirmedthat SAL0133 showed good oral absorption property, good permeability, high oralbioavailability, long half-life, good metabolic stability, and high oralexposure. GLP toxicology studies demonstrated that SAL0133 has a good safetyprofile.
If it is successfully developed and approved for marketing, itwill provide patients with new drug options to meet the unmet clinical needs.
